Genzyme/Sanofi-Aventis
On February 16 2011, Genzyme Corporation (Nasdaq: GENZ) confirmed a definitive agreement to be acquired by Sanofi-aventis (NYSE: SNY) for $74.00 per share in cash, or approximately $20.1 billion, plus one Contingent Value Right.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
-
LogicBio Therapeutics Announces Appointment of Veteran Biotech Executive Mariana Nacht, Ph.D., as Chief Scientific Officer and Kyle Chiang, Ph.D., Promoted to Chief Operating Officer
-
LogicBio Therapeutics Announces Appointment of Veteran Biotech Executive Mariana Nacht, Ph.D., as Chief Scientific Officer and Kyle Chiang, Ph.D., Promoted to Chief Operating Officer
-
LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
-
LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
-
LogicBio Therapeutics Expands Leadership Team and Bolsters Capabilities to Support GeneRide™ Platform Development and Advancement of Lead Program into Clinic
-
LogicBio Therapeutics Expands Leadership Team and Bolsters Capabilities to Support GeneRide™ Platform Development and Advancement of Lead Program into Clinic
-
Logic Devices Incorporated (LOGC) Announces Richard Moscicki MD and Michael Wyzga to Board
-
LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors
-
LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors